Sigma's Double-Digit EPS Growth Lures New Bull -- Market Talk

Dow Jones
2025/11/20

0111 GMT - Sigma Healthcare gets a new bull at UBS on the prospect of multiyear double-digit EPS growth. Initiating coverage of the stock with a buy rating, analyst Shaun Cousins tells clients that the pharmaceutical supplier's reverse takeover by the Chemist Warehouse retail group has created a capital-light business that justifies its elevated consensus multiple of 46.4X fiscal 2026 earnings. He writes in a note that operating leverage, sourcing and synergies will expand Sigma's underlying EBIT margin from fiscal 2025's pro forma 9.4% to 11.6% by fiscal 2030. UBS places a A$3.40 target price on the stock, which is up 1.0% at A$2.95. (stuart.condie@wsj.com)

 

(END) Dow Jones Newswires

November 19, 2025 20:11 ET (01:11 GMT)

Copyright (c) 2025 Dow Jones & Company, Inc.

應版權方要求,你需要登入查看該內容

免責聲明:投資有風險,本文並非投資建議,以上內容不應被視為任何金融產品的購買或出售要約、建議或邀請,作者或其他用戶的任何相關討論、評論或帖子也不應被視為此類內容。本文僅供一般參考,不考慮您的個人投資目標、財務狀況或需求。TTM對信息的準確性和完整性不承擔任何責任或保證,投資者應自行研究並在投資前尋求專業建議。

熱議股票

  1. 1
     
     
     
     
  2. 2
     
     
     
     
  3. 3
     
     
     
     
  4. 4
     
     
     
     
  5. 5
     
     
     
     
  6. 6
     
     
     
     
  7. 7
     
     
     
     
  8. 8
     
     
     
     
  9. 9
     
     
     
     
  10. 10